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least one clopidogrel prescription (11.6%) and met inclusion cri-
teria. Mean age was 67.1 years; 65.8% were male. Commonly
recorded comorbidities included: diabetes, angina, coronary
heart disease, and hypertension. Mean length of clopidogrel
therapy was 144 days. Patterns of use analysis found 42.5% of
patients stopped therapy (deﬁned as not on clopidogrel 28 days
prior to end of follow up). A gap in therapy was seen in 82.9%
(deﬁned as late reﬁlls >14 days apart). Concomitant cardiovas-
cular drug therapies included: ACE inhibitor (34.1%), beta-
blocker (12.9%), and statin (51%). CONCLUSIONS: This
descriptive study suggests clopidogrel is substantially underuti-
lized in ACS patients. Furthermore, patients had poor long-term
adherence to therapy as demonstrated by the number who
stopped therapy or had gaps. A large gap exists between current
practice and suggested treatment guidelines.
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OBJECTIVES: This research uses a Markov model of acute 
coronary syndrome (ACS) to determine the magnitudes of cost
drivers affected by new treatments. METHODS: A Markov
model was built using TreeAge Pro Healthcare and parameter-
ized to replicate the Clopidogrel in Unstable angina to prevent
Recurrent ischemic Events (CURE) trial. The model reports
results at 30 days, then every six-months over three-years for
clopidogrel plus aspirin vs. a hypothetical alternative. Reduc-
tions in risk for ﬁve events are analyzed: myocardial infarction
(MI), initial and subsequent percutaneous coronary intervention
(PCI), refractory ischemia, and stroke. Modeled risks and costs
of coronary bypass surgery and bleeding complication are not
modiﬁed. Resulting states include: no event, post each event type,
various cardiac deaths, and non-cardiac death. RESULTS: The
effects on costs of reducing relative risks of each event (and all
ﬁve together) by 10% and 20% are evaluated. Cost offsets at
one and three-years are highest for initial PCI ($239, $724;
2.0%, 2.8% of total costs for time period) for a 20% six-month
risk reduction. All other one-year offsets are less than 1.0%. Ten
percent reductions produce nearly half the cost savings. Total
savings for a 20% reduction in all ﬁve events are ($493, $1530;
4.1%, 5.8%) at one and three-years. If, instead of reducing risks
after the initial 30-day period, a 20% reduction in 30-day risk
of PTCA is modeled, then costs decrease by $389, $480, and
$616 at 30 days, one and three-years, respectively. CONCLU-
SIONS: In this model, initial PCI inﬂuences cost more than MI,
refractory ischemia, subsequent PCI, or stroke, but all are clini-
cally important. Knowing the relationship between event costs
and risk reductions can help estimate the potential cost impact
of new treatments.
CARDIOVASCULAR DISEASE—Angioplasty
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OBJECTIVES: The Clopidogrel for the Reduction of Events
During Observation (CREDO) trial showed that clopidogrel
loading prior to percutaneous coronary intervention (PCI) with
one-year treatment after PCI reduced the combined risk of death,
myocardial infarction (MI) or stroke. The purpose of this study
was to evaluate the economic impact of clopidogrel based on
CREDO in Switzerland, Belgium, Italy, and France. METHODS:
We used clinical outcomes and resource use from CREDO com-
bined with external survival data to assess the long-term cost-
effectiveness of clopidogrel. A total of 2116 patients with
coronary artery disease were randomized to clopidogrel loading
before PCI plus one year therapy (n = 1053) vs. 28 days clopi-
dogrel followed by placebo (n = 1063). All patients received
clopidogrel day zero to 28. In all, 89 (8.45%) patients in 
the treatment arm and 122 (11.48%) in the placebo group 
had an event (RRR 26.9%, 95% CI 3.9%–44.4%). Hospital-
izations were assigned a Diagnostic Related Group (DRG)
through a DRG grouper. Unit costs were developed in each
country and applied to all patients of the CREDO study. Lost
life expectancy associated with death, MI and stoke was 
estimated from Saskatchewan data and discounted 3%. Cost
effectiveness was expressed as the cost per event avoided and as
cost per Life year saved (LYS). RESULTS: The cost effectiveness
of one year use of clopidogrel in addition to a clopidogrel load-
ing strategy prior to PCI vs. placebo ranges from 15,765€ to
26,074€/event prevented. The cost per LYS is 2483€/LYS in
Belgium, 2502€/LYS in France; 2552€/LYS in Italy; 2659€/LYS
in Switzerland based on Saskatchewan projection. CONCLU-
SION: Clopidogrel used prior to PCI and for one year thereafter
is a cost effective strategy. Consistent results are found in the
four countries studied.
CARDIOVASCULAR DISEASE—Arrhythmia
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OBJECTIVE: The objective of the study was to analyze annual
health resource utilization and costs of patients with atrial ﬂutter.
While the majority of atrial ﬂutter research has focused on
various pharmacologic, cardioversion, and catheter ablation
treatment options, the costs associated with treating atrial ﬂutter
patients have not been previously reported. METHODS: All
patients receiving a diagnosis of atrial ﬂutter (ICD-9 427.32)
between January 1, and December 31, 2002 were identiﬁed from
a nationally representative private payer database (IHCIS,
Waltham, MA). Patients <18 years of age or not continuously
enrolled in a health plan for one year following the atrial ﬂutter
diagnosis were removed from the analysis. Total one-year health
resource use and costs, including hospital inpatient, outpatient,
professional, ancillary, and pharmacy services, were measured
from a third-party payer perspective. RESULTS: The study
included 4945 patients with an atrial ﬂutter diagnosis. The
average age was 62 years; 65% were male. The top co-morbid
conditions were atrial ﬁbrillation (72.3%), hypertension (55%),
and neoplasms (27%). Average total one-year medical costs for
atrial ﬂutter patients were $25,652 +/-$44,814, of which inpa-
tient hospitalizations comprised almost 50% of the total cost.
Over half of patients were hospitalized with mean length of stay
of 6.78 +/-20.73 days, 83% had at least one outpatient visit,
while almost all patients had a physician visit and 71% required
at least one pharmacy visit during the one-year follow-up. 
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CONCLUSION: Patients diagnosed with atrial ﬂutter incur sig-
niﬁcant health care costs and resource utilization. This analysis
of atrial ﬂutter patients is the ﬁrst step towards understanding
the clinical and economic burden of the disease in the United
States.
CARDIOVASCULAR DISEASE—Atrial Fibrillation
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OBJECTIVES: To determine the total direct health care costs of
patients newly diagnosed with chronic non-valvular atrial ﬁbril-
lation (CNVAF) before diagnosis and after a transient ischemic
attack (TIA), ischemic stroke (IS) or major bleed (MB).
METHODS: This retrospective, observational cohort study uti-
lized medical and pharmacy claims from a large, geographically
diverse managed care organization to identify patients with ≥two
atrial ﬁbrillation (AF) claims between January 1, 2001–June 30,
2002. Continuously enrolled members with no evidence of AF
(ICD-9-CM = 427.31) or warfarin claims 12 months prior to 
the index AF claim were followed for ≥six-months until ﬁrst
TIA/IS/MB (EVENT) or study end. Total direct health care 
costs for all patients were assessed pre- and post-AF index 
claim. For the subset of patients with an EVENT, total health
care costs were also assessed pre- and post-EVENT (from 
index AF up to EVENT, and EVENT to study end). RESULTS:
Of 3891 incidence CNVAF patients, 62% were male and 55%
were ≥65 years. Pre- and post-AF total direct health care costs
were $400 and $1073 per patient month (PPM) respectively. 
The 448 of 3891 (12%) patients with an EVENT had post-
EVENT total direct health care costs of $2311 PPM. Approxi-
mately 46% of all events occurred £one-month after the index
AF claim. CONCLUSIONS: In this population, post-AF total
direct health care costs were 2.7 times greater than pre-AF total
health care costs. For the subgroup of patients with a subsequent
TIA, IS or MB, post-EVENT total direct health care costs
increased 5.8 times from pre-AF costs with nearly half of the
events occurring within one month of AF diagnosis. Identiﬁca-
tion and treatment of CNVAF patients at risk for a cardiovas-
cular event can result in substantially lower costs to the health
care system.
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Atrial ﬁbrillation (AF) develops in some 30% of patients fol-
lowing cardiac surgery, signiﬁcantly increasing hospital length 
of stay (LOS) and costs. Previous data suggested that amio-
darone was cost-effective overall in preventing postoperative 
AF. OBJECTIVES: Using recently published epidemiological 
and clinical data, the purpose of this analysis was to assess 
the cost-effectiveness of amiodarone prophylaxis in speciﬁc
patient subgroups undergoing cardiac surgery. METHODS: A 
literature-based decision analytic model was developed from a
US payer perspective. The time horizon was the duration of
cardiac surgery hospitalization. Amiodarone plus standard of
care (beta-blocker prophylaxis) was compared to standard 
of care alone in the following patient AF risk groups: 1) age ≥
70 years, 50–69 years, and 30–49 years; 2) history of AF; and
3) concurrent valve surgery. The cost of amiodarone, LOS, physi-
cian services, adverse events, and AF treatment were included.
Sensitivity analyses were conducted to test the robustness of 
the analysis. RESULTS: In all patient populations, a 26% AF
risk reduction rate was used for amiodarone with a range of
18%–72%. Total LOS in the intensive care unit (ICU) and non-
ICU was 9.20 (ICU/non-ICU: 2.86/6.34) days in AF patients
versus 6.40 (ICU/non-ICU: 2.23/4.17) days in non-AF patients.
Amiodarone was dominant over standard of care alone in high-
risk patients (age ≥ 70 years, history of AF, or concurrent valve
surgery). The cost of amiodarone per AF event prevented was
$1,793 in patients 50–69 years and increased to $19,424 in
patients 30–49 years. The results were highly sensitive to a
change in amiodarone efﬁcacy and LOS, but less sensitive to
amiodarone drug cost. CONCLUSION: Based on this model,
amiodarone can be considered cost effective in patients under-
going cardiac surgery depending on the willingness-to-pay
threshold employed. Selection of high-risk patients improves the
cost-effectiveness ratio compared to patients with low/moderate
risk.
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OBJECTIVE: To examine race and gender cost differences asso-
ciated with treating atrial ﬁbrillation (AF) in the inpatient setting.
METHODS: This retrospective study analyzed nationally repre-
sentative hospital discharge data from the 2001 Health Care
Cost and Utilization Project (HCUP) database. The impact of
race and gender on costs of treating AF as a primary diagnosis
(ICD-9 427.31) and as a comorbid diagnosis was examined.
Using the ﬁve most frequent principal discharge diagnoses (CAD,
CHF, pneumonia, COPD, MI) with AF as a comorbid diagnosis
(case), a case/control analysis was performed to estimate annual
incremental costs of AF. Cases were matched to controls on age,
gender, race, principal discharge diagnosis, and hospital bed size.
Ordinary least squares regression was used with the following
covariates: age, gender, race, payer, bed size, emergency admis-
sion, unrelated surgery, and comorbidities. RESULTS: There
were 348,000 hospitalizations for AF as principal diagnosis with
a cost of $2.56 billion. Among the top ﬁve HCUP diagnoses with
AF as a comorbid diagnosis, there were 547,000 hospitalizations
with an incremental cost of $1.5 billion. Although race and
gender did not signiﬁcantly affect the costs of hospitalizations
for AF as a principal diagnosis, non-white race was associated
with signiﬁcantly (P < 0.001) higher costs among the top ﬁve
HCUP diagnoses with AF as a comorbid diagnosis with costs
ranging from $1216 (CHF) to $2537 (MI) per hospitalization.
Female gender was associated with signiﬁcantly increased costs
for pneumonia and COPD, but decreased costs for CHF and MI.
CONCLUSIONS: Neither gender nor race affect costs when
treating AF as a principal diagnosis. Non-white race is associ-
ated with higher costs in treating top ﬁve HCUP diagnoses with
comorbid AF.
